Efficacy of Neoadjuvant Chemohormonal Therapy for Prostate Cancer: A Systematic Review

Hua Luo's systematic review and meta-analysis, published on figshare in April 2026, synthesizes evidence from 10 studies on neoadjuvant chemohormonal therapy combined with radical prostatectomy for locally advanced prostate cancer. The 19.1 KB document analyzes outcomes including biochemical progression-free survival, positive surgical margin rates, and overall survival. It follows PRISMA guidelines and includes pooled risk ratios with 95% confidence intervals from studies searched up to August 2025.

Use Cases

• Conducting a meta-analysis on biochemical progression-free survival (BPFS) based on pooled risk ratios from 10 studies.
• Evaluating the impact of combined therapy on positive surgical margin (PSM) rates based on reported risk ratios.
• Assessing the quality of evidence for overall survival (OS) outcomes based on the GRADE certainty rating mentioned.
• Comparing treatment efficacy between randomized controlled trials and observational studies based on the subgroup analyses described.

Strengths

• Follows PRISMA guidelines for systematic review methodology.
• Includes data from 10 studies with pooled risk ratios and 95% confidence intervals for key outcomes.
• Provides subgroup analysis separating randomized controlled trials (RCTs) from non-randomized studies.

Limitations

• The dataset is a 19.1 KB DOCX document, which is a very small text summary rather than a raw research dataset.
• Row count and column-level documentation are absent; the actual underlying data tables are not provided.
• The description notes the certainty of evidence for survival outcomes is rated as 'very low' according to GRADE.

Provenance

Source

Hua Luo via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Web of Science, and Cochrane databases.

Time Range

Literature search up to August 19, 2025.

Freshness

Last updated 2026-04-20 04:13:31.